{"id":130008,"title":"GENinCode Plc (AIM: GENI) up 33% on Thermo Fisher commercialisation deal","publisher":"Share Talk","author":"sharetalk","published":"2025-12-04T09:46:52+00:00","modified":"2025-12-04T09:46:52+00:00","canonical_url":"https://www.share-talk.com/genincode-plc-aim-geni-up-33-on-thermo-fisher-commercialisation-deal/","markdown_url":"https://www.share-talk.com/genincode-plc-aim-geni-up-33-on-thermo-fisher-commercialisation-deal.md","json_url":"https://www.share-talk.com/genincode-plc-aim-geni-up-33-on-thermo-fisher-commercialisation-deal.json","category":"Health","categories":["Health","Healthcare","Pharmaceutical"],"tags":["Bernard Conrad","CARDIO","Catalonia","coronary heart disease","Genesupport","GENI","Genincode","inCode-Score®","Lab Developed","laboratories","Matthew Walls","New York","NYSDOH","ovarian cancer","Oxford","ROCA Test","Spain","Switzerland","Thermo Fisher’s QuantStudio","US revenues","USA"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2025/12/dle2Vm_7.webp?fit=1200%2C628&ssl=1","format":"news","language":"en-GB","content":"[GENinCode Plc (AIM: GENI)](https://www.investegate.co.uk/announcement/rns/genincode--geni/collaboration-with-thermo-fisher/9274793) shares climbed 33% after the company announced a major collaboration with Thermo Fisher Scientific to commercialise its CARDIO inCode-Score® Polygenic Risk Score test for predicting and preventing coronary heart disease.\n\nThe agreement covers manufacturing, sales, and distribution across the US and EMEA, with the test to be offered first as a Lab Developed Test ahead of expected FDA approval. The partnership will use Thermo Fisher’s QuantStudio™ 5 Dx Real-Time PCR System and is aimed at tapping into the sizeable cardiovascular devices markets, worth about US$22.8 billion in the US and €12.5 billion in Europe.\n\nCARDIO inCode-Score® already holds New York State licensure and is set to appear on the 2025 Clinical Laboratory Fee Schedule with an average reimbursement of around $500 per test. GENinCode said it plans to submit the remaining data required for its FDA De Novo process in the first quarter of 2026.\n\n**Matthew Walls, GENinCode Chief Executive Officer said;** “We are delighted to announce this milestone collaboration with Thermo Fisher Scientific to scale CARDIO inCode-Score across the US and EMEA markets. The collaboration advances our commercial pathway and will accelerate the adoption of CARDIO inCode-Score well beyond our current capabilities. The collaboration also underpins our US-FDA and EU-IVDR Medical Device 2026 expansion plans.” \n\nFor more information visit [www.genincode.com](http://www.genincode.com/)"}